Financial insights of SCYX

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenue	0	20,768*	-	-
Clinical expense	2,015	-	-	-
Preclinical expense	247	-	-	-
Total revenue-License And Service	-	-	334	1,364
Chemistry, manufacturing, and controls	555	-	-	-
Research and development	-	6,391*	5,452	-
Ipr&d expense	8,000	-	-	-
Selling, general and administrative	4,588	3,876*	3,287	-
Interest expense	0	0	0	0
Derivative liability fair value adjustment	-	0*	0	0
Other income	-	0*	-	-
Total operating expenses	-	10,266*	8,739	-
Warrant liability fair value adjustment	-	-1,319	640	-2,166
Gain from operations	-	10,502	-8,405	-9,561
Amortization of debt issuance costs and discount	-	0	0	0
Total other income	-	1,756	-186	2,676
Gain before taxes	-	12,258	-8,591	-6,885
Interest income	535	437	454	510
Other segment expense (income)	-6,429	-	-	-
Segment net loss	-21,299	-	-	-
Income tax expense	-	0	0	0
Adjustments and reconciling items	0	-	-	-
Net gain	-21,299	12,258	-8,591	-6,885

Basic EPS	-0.42	0.242	-0.17	-0.14
Diluted EPS	-0.42	0.242	-0.17	-0.14
Basic Average Shares	50,957,191	50,650,213	49,898,892	49,748,919
Diluted Average Shares	50,957,191	50,650,213	49,898,892	49,748,919

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.